Resting-state functional connectivity alterations in adult ADHD: A systematic review of rs-fMRI studies.

Psychiatry Res NeuroimagingJul 13, 2026 (epub)
Clinical ResearchPsychiatry

Jay Kakadiya, Beatriz A de Macedo, Neel Vora et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review analyzed resting-state functional MRI (rs-fMRI) studies to assess functional connectivity (FC) alterations in adults with ADHD compared to healthy controls. Eight studies involving 529 participants were included. The review found increased FC in the default mode, visual, and central executive networks, while decreased FC was noted in the ventral attention and somatomotor networks, predominantly in the left hemisphere.

Key findings

  • Increased FC in the default mode, visual, and central executive networks in adults with ADHD.
  • Decreased FC in the ventral attention and somatomotor networks compared to controls.
  • The review included eight studies with a total of 529 participants.
  • Alterations in FC were predominantly observed in the left hemisphere.

Why it matters

Understanding the specific functional connectivity alterations in adults with ADHD can enhance diagnostic accuracy and inform treatment strategies. This knowledge may lead to better-targeted interventions and improved patient outcomes.

Source

PubMed · PMID 42470906

Published in Psychiatry Res Neuroimaging. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.